Bevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdemaSurvival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.
Huse J, Beal K, Zhang J, Kastenhuber E, Kaley T, Abrey L, Gutin P, Brennan C, Omuro A. Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses. Journal Of Clinical Oncology 2013, 31: 2057-2057. DOI: 10.1200/jco.2013.31.15_suppl.2057.Peer-Reviewed Original ResearchMedian overall survivalOverall survivalBevacizumab treatmentSurvival benefitNanoString gene expression assaysProspective phase II trialPhase II trialNew treatment optionsParaffin-embedded tissue blocksGBM molecular subtypesMGMT promoter methylationEvaluable ptsPrimary endpointII trialUnselected patientsTreatment optionsMolecular subtypesTumor volumeStereotactic radiotherapyBevacizumabSurvival advantageTherapeutic implicationsMolecular subclassesGlioblastomaTumors